FDA Approves First Oral Therapy for EGFR Exon20 Insertion+ NSCLC 
Takeda Pharmaceutical Company Limited announced that the FDA has approved Exkivity (mobocertinib) for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. Read more.

Disparities in Lung Cancer–Screening Eligibility Persist
According to a study examining cross-sectional data from 20 states that was published in the journal Radiology, racial and ethnic disparities in lung cancer screening endure, even with revised eligibility guidelines from the U.S. Preventative Services Task Force. Read more.

Fam-Trastuzumab Deruxtecan-Nxki Promising Against HER2-Mutated NSCLC
Results from the phase II DESTINY-Lung 01 trial of fam-trastuzumab deruxtecan-nxki demonstrated robust and long-lasting antitumor activity among patients with previously treated human epidermal growth factor receptor 2 (HER-2) mutated non-small cell lung cancer (NSCLC). The results were published simultaneously in the New England Journal of Medicine. Read more.